奥美拉唑相关肌病与CYP2C19/CYP3A4药物-药物及药物-基因交互作用:嵌套病例对照研究
该嵌套病例对照研究利用电子健康记录和生物样本库数据,验证奥美拉唑与氟康唑联用增加肌病风险,并探索CYP2C19/CYP3A4多态性与奥美拉唑的药物-基因交互作用。结果显示联用氟康唑的调整比值比为1.75,CYP2C19慢代谢者合并CYP3A4中间代谢者风险更高。
要点
- 奥美拉唑联用氟康唑与肌病风险升高相关(AOR=1.75)。
- CYP2C19慢代谢合并CYP3A4中间代谢者肌病风险显著增加(AOR=4.77)。
- 临床应关注奥美拉唑联用CYP2C19/3A4抑制剂及基因多态性对肌病风险的影响。
核心结论
- 奥美拉唑与氟康唑联用增加肌病风险,CYP2C19/CYP3A4基因多态性可进一步修饰该风险。
研究设计与样本
- 采用嵌套病例对照设计,病例为奥美拉唑治疗期间发生肌病的患者,按发病密度匹配最多4名对照。
- 纳入902例病例和3608例对照进行药物-药物交互分析,862例病例和3448例对照进行药物-基因交互分析。
主要发现
- 奥美拉唑与氟康唑联用与肌病风险升高相关(AOR=1.75,95%CI 1.17-2.63,p=0.007)。
- CYP2C19慢代谢者合并CYP3A4快代谢者肌病风险升高(AOR=1.62,95%CI 1.03-2.55,p=0.036)。
- CYP2C19慢代谢者合并CYP3A4中间代谢者肌病风险更高(AOR=4.77,95%CI 1.74-13.1,p=0.002)。
临床怎么用
- 临床对奥美拉唑使用者应评估联用氟康唑等CYP2C19/3A4抑制剂的风险,并关注肌病症状。
- 必要时可结合CYP2C19和CYP3A4基因型评估肌病风险,尤其对慢代谢合并中间代谢者加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear. AIMS: This study leveraged electronic health record (EHR) and biobank data to validate an interaction between omeprazole and fluconazole and to explore drug-gene interactions (DGIs) between omeprazole and polymorphisms in CYP enzymes. MATERIALS AND METHODS: A nested case-control design with incidence-density matching was used. Cases were defined as patients who developed myopathy during ongoing omeprazole therapy. For each case, up to four controls were selected from patients who had not developed myopathy by the time the case was diagnosed. Conditional logistic regression models, adjusting for relevant covariates, evaluated (i) the association between concomitant fluconazole use and myopathy and (ii) genotype-stratified myopathy risk. RESULTS: Among 902 cases and 3608 controls, the combined use of omeprazole and fluconazole was linked to an increased risk of myopathy (adjusted odds ratio [AOR] = 1.75, 95% confidence interval [CI]: 1.17-2.63, p = 0.007). In the DGI analysis, which included 862 cases and 3448 controls, individuals classified as CYP2C19 poor metabolizers paired with CYP3A4 extensive metabolizers showed a significantly higher myopathy risk (AOR = 1.62, 95% CI: 1.03-2.55, p = 0.036); those with CYP2C19 poor metabolizer/CYP3A4 intermediate metabolizer had an even greater risk (AOR = 4.77, 95% CI: 1.74-13.1, p = 0.002). DISCUSSION: These findings not only confirm previously reported drug-drug interactions (DDIs) between omeprazole and fluconazole but also reveal the emerging clinical implications of DGIs. CONCLUSION: By integrating EHR and genetic data, the study showcases how informatics tools can translate DDI findings into DGI hypotheses, effectively bridging genetic insights and clinical outcomes.
引用
- Jeong E, Shendre A, Su Y, et al. Association of Omeprazole-Related Myopathy With Drug-Drug and Drug-Gene Interactions Involving CYP2C19 and CYP3A4: A Nested Case-Control Study. Pharmacotherapy. 2025. PMID: 40916919. doi:10.1002/phar.70058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。